drugset / Trial / NCT02263911

A Study of Baricitinib in Healthy Japanese Participants

NCT02263911

Phase 1 Completed 16 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to understand the relationship of 3 different dosage forms of baricitinib. This study will also explore the effect of food on how the body absorbs baricitinib. This study will last about 5 weeks, not including screening. Screening is required within 28 days prior to the date of first dosing.

Timeline

Start
2014-11
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 4 mg Oral
Subject Baricitinib Small molecule 8 mg Oral

Indications

No indication recorded.